CagriSema
Explore the researchResearch Guides
Research GuidesWhat cagrilintide-alone research adds to the CagriSema storyRead the 26-week monotherapy trial as evidence about a component, with its own comparator and analysis assumptions.Read guide →Research GuidesCagrilintide, semaglutide and CagriSema: verify the intervention firstA product-identity framework for understanding combination research without transferring results to different mixtures or single agents.Read guide →Research GuidesCagriSema and blood pressure: why medication review is a separate decisionInterpret the REDEFINE 1 blood-pressure analysis without treating it as permission to stop an antihypertensive medicine.Read guide →Research GuidesWould CagriSema evidence change your treatment discussion?Use comparator, endpoint, added benefit and remaining uncertainty to prepare a precise conversation about combination research.Read guide →Research GuidesCagriSema with type 2 diabetes: which trial answers which question?Distinguish REDEFINE 2, REIMAGINE 2 and the earlier phase 2 study when weighing glucose and weight outcomes.Read guide →Research GuidesDoes CagriSema prevent heart attacks? Do not transfer a component’s resultDistinguish blood-pressure findings from cardiovascular-event trials and keep semaglutide-specific evidence attached to its tested intervention.Read guide →Research GuidesWhat REDEFINE 5 contributes for readers in Japan and TaiwanExamine the regional trial’s active comparator, eligibility and analysis before applying its results to a broader population.Read guide →Research GuidesCagriSema maintenance and dose reduction: read a study plan as a planWhat the REDEFINE 8 registry can tell you about the question being tested, and why it cannot supply a tapering regimen.Read guide →Research GuidesHow to read CagriSema’s side-effect numbersDistinguish event counts, affected participants, severity and unanswered safety questions in combination trials.Read guide →Research GuidesCan you obtain CagriSema in the United States? Check status before priceA November 2026 framework for separating trial participation, approved medicines and claims about compounded cagrilintide.Read guide →Research GuidesBeyond percentage weight loss: reading CagriSema’s waist and BMI analysisUnderstand absolute body-size targets and why a post hoc association is not a personalized treatment threshold.Read guide →Research GuidesWhat CagriSema’s 20.4% result actually measuresRead REDEFINE 1 through its population, comparator, timeframe and treatment-policy estimate before using a weight-loss headline.Read guide →